FDA approves the use of ADHD patch for teenagers

07/6/2010 | Bloomberg Businessweek

The Food and Drug Administration has approved Shire's Daytrana skin patch to treat patients ages 13 to 17 who have attention-deficit/hyperactivity disorder. The treatment is already available for children ages 6 to 12 with ADHD.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
Business Development Analyst
Insight Education Group
Los Angeles, CA
Marketing Manager
Insight Education Group
Washington, DC or Los Angeles, CA
K-12 Teachers Needed at Int’l Schools
The International Educator
Multiple Locations
Account Executive
NWEA
Multiple Locations, SL_Multiple Locations
Professional Development (PD) Staff Trainer
NWEA
Multiple Locations, SL_Multiple Locations